Human genome Science 2000-Ziel: 500 Euro - 500 Beiträge pro Seite

[Geldmaschinist]

HGSI habe ich letztes Jahr bei 60 E empfohlen. Kein Stueck aus der hand geben,
z Zt. sind ganz offensichtlich Insiderkaeufe im Gange.

... denkt auch mal Celeris nach. Wer mir Verraet, wie man in diesem Board
einfuegt, dem sage ich warum.

[Geldmaschinist]

????

[Sijing]

Guten Tag Herr Geldmaschinist!

Zunächst einmal bin ich selbstverständlich erfreut, dass sich ausser meiner Wenigkeit überhaupt noch ein Wallstreet-User für diesen Wert interessiert. Dennoch eine ganz banale Frage: Woher wissen Sie dass mit den Insiderkäufen!? Sind Sie gar einer!?

Gott zum Grusse

Ihr Sijing

[Klingvestor]

Oben neben Biotech gibt es den Link Neues Thema beginnen

[Geldmaschinist]

.. Text einfuegen::.:: wie geht das ???????

[lomar]

Einfügen so geht das

Du gehst zu dem Text den du einfügen möchtest.
Jetzt Klickst du mit der linken mousetaste auf den ersten Buchstaben des Textes !!! mousetaste gedrückt halten !!!
Nun Ziehst du den Mousefeil bis zum ende des Textes nun hast du ihn Markiert.
Als nächstes läst du die linke taste los.
Gehst mit dem rechten mousefeil über den Text und drückst rechte Taste.
Jetzt Wählst du Kopieren aus.
Nu is der Text gespeichert.
Jetzt gehst du hier ins Forum machst eine neue Antwort und drückst wieder die rechte mouse taste und gehst auf einfügen.
Nun kannste deine mega news hier einfügen cu

[Geldmaschinist]

Nun kannste deine mega news hier einfügen cu

Danke!!!!!!!

du sollst dafuer reich belohnt werden!!!!


Viele haben nach meiner HGSI Empfehlung wissen wollen, was ich in 2000
kaufe. die Antwort

CELERIS

kauf bei 2, 7 E

news folgen sehr bald


GM

[Rubininvest]

HGSI jetzt gleichauf mit CHIRON !?!?..

..unglaublich ,und das alles OHNE Produkte, OHNE Umsätze und möglicherweise
sogar OHNE Zukunft ,wenn sich die Anzahl der Gentherapietoten in U.S.
weiter erhöht und damit den "Genome-hype" ad absurdum führt...

Regards
Rubininvest

[Geldmaschinist]

heute kaufen es lohnt sich,

gm

[DJWALLY]

TestDu gehst zu dem Text den du einfügen möchtest.
Jetzt Klickst du mit der linken mousetaste auf den ersten Buchstaben des Textes !!! mousetaste gedrückt halten !!!
Nun Ziehst du den Mousefeil bis zum ende des Textes nun hast du ihn Markiert.
Als nächstes läst du die linke taste los.
Gehst mit dem rechten mousefeil über den Text und drückst rechte Taste.
Jetzt Wählst du Kopieren aus.
Nu is der Text gespeichert.

[Geldmaschinist]

Human Genome Sciences Receives Patent On AIDS Virus Entry Point

ROCKVILLE, Md., Feb 16, 2000 /PRNewswire via COMTEX/ -- Human Genome Sciences,
Inc. (Nasdaq: HGSI) announced today that it was issued a U.S. patent on a human
gene that produces what is believed to be the critical entry point for the AIDS
virus. The gene, known as the CCR5 receptor gene, gives rise in human cells to a
protein that functions as a receptor or docking site for the human
immunodeficiency virus (HIV).

(Photo: http://www.newscom.com/cgi-bin/prnh/20000216/HSW003 )

Scientists learned some years ago that people who lack a functional CCR5
receptor gene are resistant to infection with HIV. The discovery suggested that
drugs that interfere with the receptor might be effective treatment for AIDS and
triggered a global race to identify suitable compounds. HGS has provided several
of its partners with licenses for the use of the CCR5 receptor gene in drug
discovery. For example, on February 8, 2000, HGS concluded an agreement with
Praecis Pharmaceuticals under which Praecis will seek to develop therapies for
AIDS by employing the CCR5 receptor gene.

The CCR5 receptor is found on the surfaces of cells. It is a member of a broad
family of human genes whose protein products, known as G-protein coupled
receptors, are targets for drugs. Examples include the histamine H-1 receptor,
targeted by the well known drug Claritin for treatment of allergies; the stomach
H-2 receptor, targeted by Zantac, Tagamet and Pepcid for acid indigestion and
ulcers; and the cerebrovascular 5-HT1 receptor, targeted by Imitrex for
treatment of migraine headaches.

HGS scientists have discovered more than 66 novel members of this class of
receptors. Together with partners, HGS has filed patents describing their
importance and medical use. Of these applications, a total of 13 patents have
been issued.

William A. Haseltine, Ph.D., Chairman and Chief Executive Officer of Human
Genome Sciences and one of the founders for the American Foundation for AIDS
Research (amfAR) commented, "The discovery of the CCR5 receptor gene is another
example of the power of the genomics approach to drug discovery. It was one of
many genes that we found very early in our discovery program. Experiments
confirmed that the CCR5 receptor played a key role in the biology of the immune
system and as an AIDS virus receptor."

HGS has filed similar patent applications that describe the medical uses of more
than 7,500 human genes discovered through HGS` genomic technologies. Patents
describing more than 2,750 of these genes have been published. HGS currently
holds 112 patents describing human genes issued by the U.S. Patent and Trademark
Office.

"This is an extremely important target and is ideal for antibody based
inhibition strategies. It fits well with HGS programs in antibody and protein
drugs," said Craig A. Rosen, Ph.D., Executive Vice President, Research and
Development. "At the same time, this receptor is an ideal target for small
molecule drug development by our partners and provides a completely different
line of attack from that afforded by nucleoside analogues and protease
inhibitors."

The patent, titled "Polynucleotides Encoding Human G-Protein Chemokine Receptor
HDGNR10," and issued as U.S. Patent No. 6,025,154, covers the DNA molecules
which encode CCR5 and vectors and host cells containing CCR5. All of the
research which led to the invention covered by this patent was carried out at
HGS, which retains the rights to use this invention.

Human Genome Sciences is a company with the mission to develop products to
predict, prevent, detect, treat and cure disease based on its leadership in the
discovery and understanding of human and microbial genes.

HGS and Human Genome Sciences are registered trademarks of Human Genome
Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit
the company`s web site at www.hgsi.com . Copies of HGS press releases are also
available by fax 24 hours a day at no charge by calling 800-758-5804, ext.
121115.

Any statements released by Human Genome Sciences, Inc. that are forward-looking
are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that forward-looking
statements involve risks and uncertainties which may affect the company`s
business prospects and performance. These include economic, competitive,
governmental, technological and other factors discussed in the company`s filings
with the Securities and Exchange Commission on forms 10-K, 10-Q and 8-K.

SOURCE Human Genome Sciences, Inc.


(C) 2000 PR Newswire. All rights reserved.



CONTACT: Kate de Santis, Director, Corporate Communications and Investor
Relations of Human Genome Sciences, 301-309-8504
/Company News On-Call: http://www.prnewswire.com/comp/121115.html or fax,
800-758-5804, ext. 121115
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000216/HSW003
AP PhotoExpress Network: PRN1
PressLink Online: 800-888-6195
PRN Photo Desk, 888-776-6555 or 201-369-3467


KEYWORD: Maryland
INDUSTRY KEYWORD: BIO
HEA

URL: http://www.hgsi.com

[kevinhomealone]

Hallo,

besucht doch mal die Biotech Foren von Handelstag.de

http://www.handelstag.de/cgi-local/branchen?ind=bio

Gruss,
Andy

[Geldmaschinist]

buy or die!1

[Geldmaschinist]

...wer jetzt nicht einsteigt, ist wahnsinnig...

die ralley wird gewaltig sein!!1

[Geldmaschinist]

I MEAN IT MAN!!!!!!!!!!!!!!!!!!!!!!!!!!!111

[IWA Japan]

Möchtst du der Pusher des Jahres werden?

[IWA Japan]

Versuche Realist zu sein und setze 200$!
500$ allerhöchstens Ende 2001, lieber Geldmaschinist

[Geldmaschinist]

....

[IWA Japan]

Ich bleibe bei meiner These: Pusher wie die sollten gnadenlos ausgesperrt werden.
Grund: Es gibt immer wieder zahlreiche Neulinge, die sich erst in die komplexe Materie einarbeiten müssen und durch so einen Dreck werden diese extrem verunsichert, was letztlich in massiven Verlusten für eben jenen unerfahrenen Anleger münden kann!

[aktienfilter]

anfänger sollten das gesamte wo meiden! grund: hier sind 90% selbst blinde euphorie-novizen, die bei mir ne gänsehaut verursachen! im wo wird dem aktienschrott die grösste aufmerksamkeit gewidmet (um himmels willen human genome zähle ich absolut nicht dazu). in allen thraeds hier sind kursziele wunsch-phantastereien! hab gerade in einem thread so eine spinnerei für tft entdeckt, bar jeden schverstandes! hier müssen viele noch lernen, daß euphorie und gier die todfeinde der börse sind! schade!

[IWA Japan]

Hallo Aktienfilter, sicherlich gibts es hier viele, die von Wunschphantasien getrieben sind.
Aber wo ist das nicht so?
Das WO-Board ist für mich, das beste Board im deutschsprachigen INternet, denn ersten ist am besten frequentiert, zweitens gibt es doch auch eine Vielzahl qualitativ guter Beiträge.
Schau mal die anderen Boards an:
Consors: 100% Pusher
Stock.city: autoritär von einem 22 jährigen Informatik-Studenten geführt geführt

BO schlechte Struktur wie Consors
Ariva, stockworld,.. geringe Besucherfrequenz

Ich bevorzuge hier eher etwas aggressivere Threads, in denen ich versuche, anderen Leuten diesbezüglich die Augen zu öffnen, wen ich auch schon mal übers Ziel hinausschieße.

Die Leute werden aber schon merken, wenn ihre Nebenwerte den BAch hinuntergehen.
Beispiel: Schau mal die ADS-Threads an: Habe hier massive Kritik geerntet, weil viele solcher Wunschdenker nicht wahrhaben wollen, dass ADS momentan eher gemieden werden sollte, da die Fundamentals zur Zeit nicht stimmen. Es sind halt viele bei 40-50€ rein, vielleicht auch wegen einer 300€ Empfehlung auf einem anderen Board.
Aber ich will jetzt keinen neuen ADS-THread eröffnen, da ich erklärt habe, mich momentan nicht mehr an ADS THreads zu beteiligen!

[Geldmaschinist]

es freut mich das hier eine so lebhafte Diskussion zu Thema HGSI ensteht.
Und morgen könne wir Glückspilze nochmals kräftig nachkaufen - mit 4% preisnachlas.

Buy or Die

GM

[Geldmaschinist]

...

[Geldmaschinist]

.. siehste!!!!

jetzt koennen die Kritikaster und Ungläubigen wieder den Kursen hinterherrennen.

hgsi ist nun mal ne Geldmaschine, oder so


jetzt einsteigen . es ist niemals zu spät.


GM

[Geldmaschinist]

...


ooops - i did it again ....

[Geldmaschinist]

Friday June 23, 4:00 am Eastern Time
Company Press Release
SOURCE: Human Genome Sciences, Inc.

Human Genome Sciences to Initiate Human Clinical Trials of BLyS
Trials to Begin Only One Year After Discovery Announced


ROCKVILLE, Md., June 23 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - news) today announced that it will
initiate human clinical trials of B-lymphocyte stimulator, or BLyS, in patients with Common Variable Immunodeficiency, a serious
defect of the immune system. These plans follow a review of HGS` Investigational New Drug application with the U.S. Food and Drug
Administration.

(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000623/DCF006-a
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000623/DCF006-b

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000623/DCF006-c

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000623/DCF006-d )

Common Variable Immunodeficiency, or CVID, is one of a group of primary immunodeficiency disorders that are characterized by
increased susceptibility to infection. Affected individuals suffer from multiple bouts of pneumonia, bronchitis and sinusitis as well as
other infections. Patients suffering from CVID require life-long treatment with antibodies to protect against recurrent infection.

BLyS is a protein made by the human body that stimulates the production of antibodies. Antibodies recognize foreign substances
and help defend the body against infection by viruses, bacteria and other microorganisms. Patients with CVID fail to make normal
quantities of antibodies, or immunoglobulins, making them susceptible to infections. The hope is that by providing BLyS to these
patients, they will be able to produce their own antibodies and ward off infections themselves.

Jerry Winkelstein, M.D., Eudowood Professor of Pediatrics at Johns Hopkins University and Chair of the Medical Advisory
Committee to the Immune Deficiency Foundation, said, ``Patients with Common Variable Immunodeficiency are unable to make
adequate amounts of their own antibodies. As a result, they have to depend on antibody treatments for the rest of their life. BLyS
may restore their ability to produce antibodies again, which would be a very important advance in their treatment.``

David C. Stump, M.D., Senior Vice President, Drug Development of Human Genome Sciences, said, ``We are very excited about the
prospect of studying BLyS in patients with Common Variable Immunodeficiency. Like human growth hormone or insulin, BLyS is a
natural substance made by the human body. It is our hope that BLyS will relieve the symptoms of CVID patients suffering from this
life-long debilitating disorder.``

Craig A. Rosen, Ph.D. Executive Vice President, Research and Development of Human Genome Sciences, said, ``We are initiating
human clinical trials of BLyS one year after publishing the news of the protein`s discovery and description of its activity in the
immune system in Science magazine in July of 1999. The rapid progress from bench to clinic of this new drug is a tribute to the
concerted efforts of our drug discovery, development and manufacturing teams as well as to the efforts of our clinical development
and regulatory staff.``

William A. Haseltine, Ph.D., Chairman and Chief Executive Officer of Human Genome Sciences, said, ``The development of BLyS as
a candidate to treat this disease, Common Variable Immunodeficiency, and possibly the use of this drug to treat other forms of
immune deficiency disease, is an example of our systematic approach to converting knowledge of human genes into drugs to treat
serious diseases. We did not discover BLyS by accident, rather we designed a functional proteomics approach to search for
naturally occurring substances, proteins made by human genes that stimulate immune function and trigger the production of
antibodies. BLyS is one of about 10,000 human proteins that we have evaluated for their potential medical use. Once the BLyS
protein was shown to stimulate antibody production, our team of scientists and physicians moved quickly to produce enough protein
to conduct the extensive laboratory tests of safety and efficacy needed to initiate human clinical trials.``

For more information about Primary Immunodeficiencies, contact the Immune Deficiency Foundation at 800-296-4433, or visit their
website at www.primaryimmune.org.

Individuals interested in BLyS or in Common Variable Immunodeficiency clinical trials are encouraged to contact Human Genome
Sciences at (301) 309- 8504 extension 3550, or via the Internet at www.hgsi.com.

Human Genome Sciences is a company with the mission to treat and cure disease by bringing new gene-based drugs to patients.

HGS and Human Genome Sciences are registered trademarks of Human Genome Sciences, Inc. For additional information on
Human Genome Sciences, Inc., visit the company`s web site at www.hgsi.com. Copies of HGSI press releases are also available by
fax 24 hours a day at no charge by calling 800-758-5804, ext. 121115. For additional information on BLyS and Common Variable
Immunodeficiency please see additional background information attached to a copy of the press release on the HGS website. For
more information about HGS` effort to discover cell to cell signaling molecules and high throughput functional genomics program,
visit the HGS website and click on ``Functional Genomics Program.``

Any statements released by Human Genome Sciences, Inc. that are forward looking are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that forward looking statements involve risks and
uncertainties which may affect the company`s business prospects and performance. These include economic, competitive,
governmental, technological and other factors discussed in the company`s filings with the Securities and Exchange Commission on
forms 10-K, 10-Q and 8-K.


B LYMPHOCYTE STIMULATOR

Background


In July 1999, Human Genome Sciences (HGS) reported the discovery of a novel human protein called B Lymphocyte Stimulator, or
BLyS. (1) BLyS stimulates immune system cells called B cells to mature into plasma B cells, which produce antibodies (see Fig.
1). Plasma B cells and the antibodies they produce constitute a critical part of the body`s defense against infections and cancer.

Fig. 1: BLyS released from monocytes activates resting B cells, stimulating them to become plasma B cells that secrete antibodies.


The discovery of BLyS may lead to therapies for several diseases that involve B cells, including immune deficiencies, autoimmune
disease and B cell tumors. HGS` drug development teams are advancing several therapeutic concepts based on the discovery of
BLyS: BLyS therapeutic protein, anti-BLyS, and radiolabeled BLyS.

How BLyS Works

BLyS is made by immune-cells called monocytes and macrophages. When monocytes and macrophages are activated, BLyS is
released and binds to a receptor found only on B cells. B cells arise from stem cells that do not themselves produce antibodies.
When BLyS binds to its receptor on B cells, they mature into antibody-secreting plasma B cells. As a result, the number of
antibodies in the patient`s plasma increases.

When antibodies recognize foreign molecules, immune-cells target the molecules for destruction. Without plasma B cells and
antibodies, the body is largely unprotected against pathogens, and infectious disease may follow.

TURNING BLyS INTO TECHNOLOGY FOR FIGHTING HUMAN DISEASE

BLyS Therapeutic Protein for Immunodeficiency

Immunodeficiency disorders are a diverse group of conditions caused by one or more immune system defects. They are
characterized by increased susceptibility to infections with consequent severe, acute, recurrent or chronic disease. Physicians
recognize more than 70 different primary immunodeficiencies-ones that are caused by abnormalities in the development of immune
system cells. Increased susceptibility to infections as a consequence of decreasing antibody output is common in people older than
70. Antibody deficits leading to increased incidence of serious infections also occur in cancer patients, and in immunosuppressed
transplant recipients. The HGS BLyS Therapeutic Protein Program is developing BLyS protein as a therapeutic agent that may be
valuable in the treatment of all of these groups (see Fig. 2).

Fig. 2: BLyS protein stimulates B cells to produce antibodies.

Primary Immunodeficiency: CVID

Common variable immunodeficiency (CVID) is a group of immunodeficiency syndromes in which B cell immunity is abnormal. Most
patients have normal or near-normal numbers of circulating B cells, but the cells fail to differentiate into effective plasma B cells. As
a result, patients have low or undetectable amounts of serum antibodies. The condition may result from insufficient stimulation of B
cells rather than from a failure intrinsic to B cells. (2)

There are several thousand CVID patients in the United States and Europe. CVID occurs equally in both genders. Most patients
experience acute, recurring bacterial infections, including pneumonia, bronchitis and sinusitis. (3) Current treatment involves regular
administration of intravenous antibodies, which are prepared from pooled blood samples from thousands of individual donors.

BLyS protein may boost antibody levels in patients with CVID, as well as in other immunodeficiency conditions that effectively mimic
CVID. HGS scientists have found in laboratory studies that BLyS boosts antibody production in B cells isolated from some CVID
patients.

Older Patients

Patients older than 70 years suffer significantly more from infectious disease and die more frequently from infections than younger
people. This is believed to be in large part a result of age-related declines in the effectiveness of the immune system. BLyS may be
able to stimulate immune system function in elderly patients.

Cancer and Transplant Patients

Several types of cancer, including chronic lymphocytic leukemia and multiple myeloma, affect the immune system`s ability to fight
off infections by impairing antibody production. BLyS may help these patients fend off infectious disease. Cancer therapies also
damage the immune system. In some cases it may take years for the full antibody response to recover following cancer treatment.
Treatment with BLyS after cancer therapy may speed recovery of a fully competent immune system.

Transplant recipients have to take immunosuppressive drugs that make them vulnerable to infections of all sorts. BLyS may be able
to help such patients maintain an immune system that is capable of combating infectious disease.

Patients with Infectious Diseases

Many bacterial infections that are resistant to treatment with antibiotics are able to persist because of an inadequate immune
response. BLyS may be able to improve immune defenses in such patients. In addition, it is possible that BLyS protein may be
useful when combined with vaccines. Vaccines work, in part, by inducing the production of antibodies that recognize invading
organisms. Used as a vaccine adjuvant, BLyS may enhance the effectiveness of a wide range of vaccine candidates by stimulating B
cell production and so strengthening the immune response to the vaccine.

BLyS Antagonists for Autoimmune Disease and Cancer
Autoimmune Disease
The immune system has to distinguish the body`s own cells and tissues from

those of pathogens so that it can avoid attacking itself while maintaining a
diverse repertoire of antibodies. Abnormalities in the induction or
maintenance of self-tolerance-the process that prevents the immune system from
attacking the body`s own tissues-can lead to inflammatory immune responses
developing against self-antigens and thus to autoimmune disease. B cells that
produce antibodies that recognize parts of the normal body play an important
role in many autoimmune diseases. Systemic lupus erythromatosis, rheumatoid
arthritis, multiple sclerosis, Crohn`s disease, diabetes, and some forms of
asthma are all examples of autoimmune diseases.
Fig. 3: Anti-BLyS molecules prevent BLyS from having its normal effect and so block the overproduction of antibodies.

HGS scientists are creating human monoclonal antibodies that bind to BLyS and inactivate the BLyS protein (see Fig. 3). It is
already known that overproduction of BLyS in animals leads to a lupus-like disease. (4) Experiments in models of autoimmune
disease suggest that such BLyS antagonists may reduce the body`s ability to produce harmful self-reactive antibodies, with
consequent benefits for patients.

B Cell Cancers

B cells are centrally involved in certain types of cancer, including non- Hodgkin`s lymphoma, chronic lymphocytic leukemia and
multiple myeloma. In these diseases, B cells become malignant and grow in an unregulated fashion.

Non-Hodgkin`s lymphoma is the fifth-most-common type of cancer diagnosed in the U.S. each year. Chronic lymphocytic leukemia
is the most common form of leukemia. Multiple myeloma is a deadly form of B cell cancer with a five-year survival rate of 28 per
cent. New therapies are needed to improve survival rates and bring cures to more patients with these forms of cancer.

Fig. 4: BLyS protein attached to a radioisotope such as iodine-131 may bind to BLyS receptors on cancerous B cells and kill the
cells with low doses of radiation.

Radiolabelled BLyS

BLyS linked to radionucleotides have a potential application as therapy for B-cell malignancies. Such malignancies are responsive to
radiation, and radiotherapy is an important part of the treatment plan for many patients with these diseases. A drug consisting of
BLyS linked to a source of radiation would bind only to B cells, so low doses of radiation would be effective at killing such cells (see
Fig. 4). HGS is evaluating technologies that will allow a radioisotope to be linked to BLyS to create drugs that bind to and kill
B-cells.

How BLyS Was Discovered

A Functional Proteomics Success Story


HGS scientists discovered BLyS (B Lymphocyte Stimulator) via functional proteomics, the study of the natural function and medical
use of proteins discovered by genomic technology.

For decades, scientists sought a biological signal that stimulates immune- cells called B cells to become plasma B cells, which
produce antibodies. Because biological signals are often secreted proteins, HGS scientists were studying a group of about 400
human proteins in the HGS database whose DNA sequences suggested that they were secreted. Each protein was purified and
tested for the ability to stimulate B cell growth. One protein, BLyS, had a powerful effect on B cells.

Just as important, BLyS lacked effects on other cells. In pre-clinical experiments, BLyS was found to increase the production of
antibodies, immediately suggesting medical applications in the treatment of immunodeficiencies and possibly other conditions. The
HGSI scientists published the BLyS research in Science magazine in July 1999. (1)

The HGS functional proteomics program currently examines the biological activity of 10,000 human secreted proteins in the search
for those that may serve as useful drugs. Human proteins identified through genomics may have medical properties superior to
conventional small-molecule drugs, and may enter clinical trials more quickly, because less medicinal chemistry research is needed
to turn them into product candidates. Human antibodies to human genes and proteins may prove to be important medicines, and
HGS is pursuing medicines based on antibodies to BLyS through several collaborations.

Conclusions

The discovery of BLyS, a long-sought key immune system regulator with multiple possible uses in medicine, exemplifies the power
of genomics to find molecules with therapeutic potential. Standard biochemical techniques had failed to identify BLyS, but
systematic screening of proteins produced by candidate human genes revealed its identity and its powerful influence on the immune
system. Genomics and proteomics may yield many additional potent molecules with medical applications.

References:
1. Paul A. Moore, Ornella Belvedere, Amy Orr, Krystyna Pieri, David W.
LaFleur, Ping Feng, Daniel Soppet, Meghan Charters, Reiner Gentz,
David Parmelee, Yuling Li, Olga Galperina, Judith Giri, Viktor
Roschke, Bernardetta Nardelli, Jeffrey Carrell, Svetlana Sosnovtseva,
Wilbert Greenfield, Steven M. Ruben, Henrik S. Olsen, James Fikes, and
David M. Hilbert. BLyS: Member of the Tumor Necrosis Factor Family and

B Lymphocyte Stimulator. Science, Vol. 285, Number 5425, 260-263. July
9, 1999.
2. F. Rosen et. al. The Primary Immunodeficiencies, A Review Article. New
England Journal of Medicine 333: 7, August 17, 1995.
3. Immune Deficiency and Allied Disorders: Clinical Updates, Immune
Deficiency Foundation Vol. II, Issue 1, July 1995.
4. Mice transgenic for BAFF develop lymphocytic disorders along with
autoimmune manifestations. Mackay F, Woodcock SA, Lawton P, Ambrose C,
Baetscher M, Schneider P, Tschopp J, and Browning JL. J Exp Med 1999
Dec 6; 190(11): 1697-1710.


COMMON VARIABLE IMMUNODEFICIENCY


Definition

Common variable immunodeficiency (CVID) is one of a mixed group of diseases in which the production of antibodies is defective,
exposing patients to increased risk of life-threatening infections. Most patients with CVID experience acute, recurring bacterial
infections, including pneumonia, bronchitis and sinusitis. Autoimmune conditions and gastrointestinal diseases also may occur in
some CVID patients. Children with CVID are susceptible to otitis media, and infections may develop in the joints, bones, skin and
parotid glands. In addition, CVID patients are at increased risk of cancer and inflammatory conditions.

Clinically, CVID may resemble HIV infection, as it may cause weight loss, swelling of the lymph nodes, diarrhea, lymphoma, and
idiopathic thrombocytopenic purpura (a condition in which blood improperly escapes into tissues). The opportunistic infections
characteristic of HIV/AIDS are, however, rare.

The precise cause of CVID is uncertain and may vary among patients. In healthy people, B cells in the blood, which carry
immunoglobulins (antibodies) on their exterior, mature into plasma B cells. These then secrete antibodies that help fight infections.

Many patients with CVID have near-normal numbers of antibody-bearing B cells, but these fail to mature into plasma B cells. As a
result, these patients have low or undetectable amounts of the immunoglobulins IgG, IgA and IgM in their serum. Other CVID
patients have low numbers of B cells, however, and some have abnormalities of the other main branch of the immune system, the
cell-mediated (T-cell) arm.

A growing body of evidence indicates that some patients may be genetically predisposed to CVID, but environmental factors may
also modify the form of CVID and its progression. Among the possible causes are B-cell and T-cell defects, and abnormalities in the
interactions of B and T cells.

CVID is the most common clinically significant primary immunodeficiency disease and affects several thousand patients in the
United States and Europe. It occurs equally in both sexes. It may become apparent in infancy or as late as the fifth decade of life.
The average age of onset is 27 years. In the past, the terms late-onset hypogammaglobulinemia, adult-onset agammaglobulinemia
and acquired agammaglobulinemia have been used to describe CVID.

Treatment

The current treatment for CVID is prophylactic administration of human immunoglobulin every 3 weeks throughout the patient`s life,
along with systemic antibiotics as necessary for the management of concomitant infections.

Unmet Need

Clinicians need more efficacious therapies that can better control the infections and other complications of CVID and lack some of
the disadvantages of immunoglobulins. The human protein B Lymphocyte Stimulator (BLyS) may help CVID patients produce their
own antibodies to protect them from infections.

SOURCE: Human Genome Sciences, Inc.

[Geldmaschinist]

oops .......????

[m.lynched]

@ Geldmaschinist:
Die URL von HGSI in den Browser zu tippen und die Infos zu lesen, schaff ich so gerade noch selber. Wolltest Du dafür wissen, wie man Texte kopiert und einfügt? Die Adresse anzugeben hätte völlig ausgereicht. Wenn Du hier etwas Konstruktives beitragen willst, dann poste statt unbegründeten Kurszielen lieber mal eine Zusammenfassung der Nachrichten, vielleicht auf Deutsch!
Habe selber HGSI und nichts dagegen, wenn die durch die Decke knallen, aber hier ohne weitere Begründungen Kursziele von 500 zu verkünden, wirkt ausgesprochen unsachlich. Ne, Lemminge fängt man anders!

gruß, ml

[zak2000]

Schön, dass das ziel so hoch gesteckt wird. in welcher relation steht den diese plumpe aussage. 250 Eur ist realistisch, aber 500?

zwar arbeitet human genome nun mit aventis zusammen, d.h. gute vertriebsmöglichkeiten. aber 500 EUR, tse.

euer zak2000

[Geldmaschinist]

.. wieso ?? freu dich doch...

[Geldmaschinist]

ter 05.07.00 12:40:52 1233460
Name Human Genome Sciences, Inc. HGSI Börsen - Handelsplätze:

Nasdaq-NM
Xetra
Frankfurt
Berlin
München
Stuttgart
Hamburg
Sitz der Gesellschaft


9410 Key West Avenue Rockville,
MD 20850-3331
301-309-8504


Telefon [phone]
Fax [phone]
eMail

[e-mail]

Internet

www.hgsi.com

Schwerpunkt

Entwicklung und Herstellung protein- und genbasierter Medikamente

Aktionärsstruktur
<keine Angabe>

Geschäftsjahresende 31. Dezember
Währung US-Dollar
Beschäftigte

505
Umsatz
(1999/1998/1997) <keine Angabe>
Jahresüberschuss
(1999/1998/1997)

<keine Angabe>





Portrait:

Human Genome Sciences erforscht und entwickelt patentgeschützte pharmazeutische und diagnostische Produkte, die auf Genen
basieren. In ihren umfangreichen Datenbanken hat das 1992 von Dr. William Haseltine gegründete Unternehmen Informationen über
menschliche Genabschnitte und Genen von Mikroorganismen gespeichert, die als Grundlage für die Forschung und Entwicklung von
neuartigen Medikamenten verwendet werden.

Die Aktie wurde zum ersten mal am 02.12.1993 an der Börse gehandelt. Nach einer positiv verlaufenden Kursentwicklung erfolgte
am 28.01.2000 ein Aktiensplit im Verhältnis 2:1. Dem kräftigen Kursanstieg im Februar 2000 folgte dann im März eine starke
Kurskorrektur und der Aktienkurs sackte von seinem Höchstkurs von 215$ auf zeitweilig unter 65$ ab.

Zur Zeit befinden sich drei Medikamente, an deren Entwicklung HGS maßgeblich beteiligt ist, in der Phase III: KGF-2, MPIF-1 und
VEGF-2. Die ersten beiden Medikamente sollen empfindliches Körpergewebe vor den schädigenden Nebenwirkungen von
Krebstherapien schützen. Das dritte Medikament von Vascular Genetics Inc., ein Joint Venture, das von HGS angeführt wird, soll die
Neubildung von Blutgefäßen im Herzbereich und in den Gliedmaßen fördern.

Human Genomes Sciences Gendatenbanken werden von zahlreichen großen Pharmaziekonzernen genutzt, die dadurch ihre
Entwicklung und Forschung von neuen Produkten beschleunigen. Unter den Konsortialpartnern sind renomierte Firmen wie
Schering-Plough, SmithKline Beecham, Takeda Chemical, Synthelabo, und Merck KGaA. HGS erhält von diesen Unternehmen hohe
Zahlungen, die mittlerweile schon mehr als 220 Millionen Dollar betragen haben und den Pharmaziekonzernen Zugriff auf die
Gendatenbanken von Human Genome Sciences sichern. Die Verträge mit Human Genome Sciences Konsortialpartnern laufen im
Juli.2001 aus. Danach wird HGS alleinigen Zugriff auf seine Technologie besitzen, um selber Produkte zu entwickeln und zu
lizensieren. Schon jetzt besitzt Human Genome Sciences das Recht, selber bestimmte Medikamente auf molekularer Basis zu
entwickeln und zu lizensieren.

Im Bereich der Gen Therapie ist Human Genome Sciences 1998 eine strategische Allianz mit Transgene S.A., Strasbourg,
Frankreich eingegangen. Mit Schering-Plough ist HGS eine Vereinbarung eingegangen, wonach Schering-Plough Gen-Technologien
für die Entwicklung und Vermarktung von neuartigen Gen Therapie-Methoden einsetzen darf. Human Genome Sciences erhält dafür
jährliche Zahlungen, sowie Zusatzprämien für sehr erfolgreiche Produkte, die mit Hilfe der HGS Technologie entwickelt wurden.

Entdeckungen die Human Genome Sciences bei Bakteriengene gemacht hat, teilt es mit anderen Pharmazieunternehmen. Bei
Antikörpern arbeitet HGS mit F. Hoffmann-La Roche und Pharmacia & Upjohn, bei Immuntherapeutik mit Pasteur Merieux
Connaught/Oravax und MedImmune zusammen. Im Bereich der Bakteriengene hat HGS kaum Exklusiv-Verträge abgeschlossen und
ist somit bei der Entwicklung neuer Produkte nicht vertraglich an große Pharmaziekonzerne gebunden.

HGS Hauptsitz befindet sich in Rockville, Maryland und das Unternehmen ist an der NASDAQ notiert.